Related Experiment Videos
[Classification and pathogenesis of lung carcinoma]
Elisabeth Brambilla1, Sylvie Lantuejoul, Nathalie Sturm
1Groupe de recherche sur le cancer bronchique INSERM U. 9924 Laboratoire de pathologie cellulaire Centre hospitalier universitaire de Grenoble 38043 Grenoble. EBrambilla@chu-grenoble.fr
La Revue Du Praticien
|July 26, 2003
Summary
The World Health Organization/International Association for the Study of Lung Cancer (WHO/IASLC) 1999 classification is the standard for lung tumor histology. This system aids in understanding lung cancer subtypes, their origins, and guiding patient treatment strategies.
Area of Science:
- Pulmonology and Oncology
- Cancer Histopathology
Context:
- The World Health Organization/International Association for the Study of Lung Cancer (WHO/IASLC) 1999 classification is the international standard for lung tumor histology.
- Lung cancers, predominantly squamous cell carcinoma, adenocarcinoma, small cell carcinoma, and large cell carcinoma, are linked to tobacco smoke carcinogens.
- Tumor heterogeneity and multifocal preinvasive lesions are common due to stem cell derivation and field cancerization.
Purpose:
- To provide a standardized histologic classification for lung tumors.
- To establish a basis for clinical, biological, and epidemiological research in lung cancer.
- To facilitate patient stratification for clinical trials and therapeutic agent sensitivity/resistance studies.
Summary:
- The 1999 WHO/IASLC classification categorizes lung tumors into major types, primarily linked to tobacco carcinogens.
- It acknowledges tumor heterogeneity and the field cancerization process affecting the bronchial tree.
- This classification serves as a crucial tool for research and clinical trial enrollment.
Impact:
- Enhances understanding of lung cancer subtypes and their origins.
- Provides a foundation for targeted therapies and clinical trial design.
- Improves the interpretation of patient responses to novel therapeutic agents.